Published May 31, 2024 | Version v1
Journal article Open

The Budd-Chiari Syndrome as a Complication of Paroxysmal Nocturnal Hemoglobinuria (Clinical Case)

Authors/Creators

  • 1. Bogomolets National Medical University, Ukraine

Description

Among the main causes of recurrent thrombosis in young patients there is paroxysmal nocturnal hemoglobinuria (PNH), a complication of which is Budd-Chiari syndrome (BCS), characterized by thrombosis of the hepatic veins and/or inferior vena cava. Detection of PNH is an extremely important task, because its untimely diagnosis leads to recurrent thrombosis, deterioration of the patient’s quality of life, and increased mortality from complications which accompany PNH.

The article analyzes a clinical case of PNH in a young patient with recurrent BCS, which illustrates the relevance and timely diagnosis of this disease. As a result of unsuccessful pharmacological treatment and progression of liver insufficiency, the patient had liver transplantation. After surgery and standard post-transplantation therapy the patient’s condition improved, but after some time a recurrence of hepatic vein thrombosis was developed. After hematologist consultation and performing flow cytometry, the patient was diagnosed PNH. However, on the background of recurrent hepatic vein thrombosis, immunosuppressive therapy, and the lack of targeted treatment for PNH, multiple organ failure was developed, which led to the patient’s death.

PNG is one of the orphan diseases, which is characterized by a severe, chronic, progressive course and accompanied by the formation of degenerative changes in the body, a decrease in the quality and shortening of the patient’s life. Targeted therapy can reduce the risk of thrombosis, red blood cell transfusions and improve the quality of life of patients with PNH.

Other

https://family-medicine.com.ua/article/view/307537

Files

The_Budd_Chiari_Syndrome_as_a_Complication_of_Paroxysmal_Nocturnal_Hemoglobinuria_Clinical_Case.pdf

Files (1.6 MB)

Additional details

References

  • Campello E, Spiezia L, Adamo A, Simioni P. Thrombophilia, risk factors and prevention. Expert Rev Hematol. 2019;12(3):147–58. doi: 10.1080/17474086.2019.1583555.
  • Hitawala AA, Gupta V. Budd-Chiari Syndrome [Internet]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https://pubmed.ncbi.nlm.nih.gov/32644367/.
  • Clinical Practice Guidelines. EASL Clinical Practice Guidelines: Vascular diseases of the liver. J Hepatol. 2016;64:179–202. doi: 10.1016/j.jhep.2015.07.040.
  • Hill A, DeZern AE, Kinoshita T, Brodsky RA. Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers. 2017;3:17028. doi: 10.1038/nrdp.2017.28.
  • Röth A, Maciejewski J, Nishimura JI, Jain D, Weitz JI. Screening and diagnostic clinical algorithm for paroxysmal nocturneal hemoglobinuria: Expert consensus. Eur J Haematol. 2018;101(1):3–11. doi: 10.1111/ejh.13059.
  • Yu F, Du Y, Han B. A comparative analysis of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria between Asia and Europe/America. Int J Hematol. 2016;103(6):649–54. doi: 10.1007/s12185-016-1995-1.
  • Ware RE, Hall SE, Rosse WF. Paroxysmal nocturnal hemoglobinuria with onset in childhood and adolescence. N Engl J Med. 1991;325(14):991–6. doi: 10.1056/NEJM199110033251403.
  • Naithani R, Mahapatra M, Dutta P, Kumar R, Pati HP, Choudhry VP. Paroxysmal nocturnal hemoglobinuria in childhood and adolescence – a retrospective analysis of 18 cases. Indian J Pediatr. 2008;75(6):575–8. doi: 10.1007/s12098-008-0111-9.
  • Curran KJ, Kernan NA, Prockop SE, Scaradavou A, Small TN, et al. Paroxysmal nocturnal hemoglobinuria in pediatric patients. Pediatr Blood Cancer. 2012;59(3):525–9. doi: 10.1002/pbc.23410.
  • van den Heuvel-Eibrink MM, Bredius RG, te Winkel ML, Tamminga R, de Kraker J, Schouten-van Meeteren AY, et al. Childhood paroxysmal nocturnal haemoglobinuria (PNH), a report of 11 cases in the Netherlands. Br J Haematol. 2005;128(4):571–7. doi: 10.1111/j.1365-2141.2004.05337.x.
  • Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood. 2013;121(25):4985–96. doi: 10.1182/blood-2012-09-311381.
  • Kim H, Kim IS, Cho SH, Lee HJ, Chang CL, Yoon KT. The first case of paroxysmal nocturnal hemoglobinuria and Budd-Chiari syndrome treated with complement inhibitor eculizumab in Korea. Blood Res. 2017;52(2):145–8. doi: 10.5045/br.2017.52.2.145.
  • Meyers G, Weitz I, Lamy T, Jean-Yves Cahn, Kroon H-A, Severino Beth, et al. Disease-related symptoms reported across a broad population of patients with paroxysmal nocturnal hemoglobinuria. Blood 2007;110(11):3683. doi: 10.1182/blood.V110.11.3683.3683.
  • Hill A, Rother RP, Wang X, Morris SM Jr, Quinn-Senger K, Kelly R, et al. Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2010;149(3):414–25. doi: 10.1111/j.1365-2141.2010.08096.x.
  • Parker CJ. Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria. Hematology Am Soc Hematol Educ Program. 2016;2016(1):208–16. doi: 10.1182/asheducation-2016.1.208.
  • Brando B, Gatti A, Preijers F. Flow Cytometric Diagnosis of Paroxysmal Nocturnal Hemoglobinuria: Pearls and Pitfalls – A Critical Review Article. EJIFCC. 2019;30(4):355–70.
  • Pu JJ, Mukhina G, Wang H, Savage WJ, Brodsky RA. Natural history of paroxysmal nocturnal hemoglobinuria clones in patients presenting as aplastic anemia. Eur J Haematol. 2011;87(1):37–45. doi: 10.1111/j.1600-0609.2011.01615.x.
  • Helley D, de Latour RP, Porcher R, Rodrigues CA, Galy-Fauroux I, Matheron J, et al. Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Haematol. 2010;95(4):574-81. doi: 10.3324/haematol.2009.016121.
  • Socié G, Schrezenmeier H, Muus P, Lisukov I, Röth A, Kulasekararaj A, et al. Changing prognosis in paroxysmal nocturnal haemoglobinuria disease subcategories: an analysis of the International PNH Registry. Intern Med J. 2016;46(9):1044–53. doi: 10.1111/imj.13160.
  • Sørensen AL, Lund Hansen D, Frederiksen H. Early Mortality in Paroxysmal Nocturnal Hemoglobinuria. Cureus. 2023;15(10):e47225. doi: 10.7759/cureus.47225.
  • de Latour RP Terriou L, Etienne G, Mohty M, et al. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood. 2008;112:3099–106. doi: 10.1182/blood-2008-01-133918.
  • Cançado RD, Araújo ADS, Sandes AF, Arrais C, Lobo CLC, Figueiredo MS, et al. Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria. Hematol Transfus Cell Ther. 2021;43(3):341–8. doi: 10.1016/j.htct.2020.06.006.
  • Hillmen P, Muus P, Dührsen U, Risitano AM, Schubert J, Luzzatto L, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007;110(12):4123–8. doi: 10.1182/blood-2007-06-095646.
  • Kelly RJ, Brooksbank GL, Richards SJ, Cullen M, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 2011;117:6786–92. doi: 10.1182/blood-2011-02-333997.
  • Weitz IC, Razavi P, Rochanda L, Zwicker J, Furie B, Manly D, et al. Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation. Thromb Res. 2012;130(3):361–8. doi: 10.1016/j.thromres.2012.04.001.
  • Gembillo G, Siligato R, Cernaro V, Santoro D. Complement Inhibition Therapy and Dialytic Strategies in Paroxysmal Nocturnal Hemoglobinuria: The Nephrologist's Opinion. J Clin Med. 2020;9(5):1261. doi: 10.3390/jcm9051261.
  • Emadi A, Brodsky RA. Successful discontinuation of anticoagulation following eculizumab administration in paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2009;84(10):699–701. doi: 10.1002/ajh.21506.
  • Araten DJ, Notaro R, Thaler HT, Kernan N, Boulad F, Castro-Malaspina H, et al. Thrombolytic therapy is effective in paroxysmal nocturnal hemoglobinuria: a series of nine patients and a review of the literature. Haematologica. 2012;97(3):344–52. doi: 10.3324/haematol.2011.049767.
  • Singer AL, Locke JE, Stewart ZA, Lonze BE, Hamilton JP, Scudiere JR, et al. Successful liver transplantation for Budd-Chiari syndrome in a patient with paroxysmal nocturnal hemoglobinuria treated with the anti-complement antibody eculizumab. Liver Transpl. 2009;15(5):540–3. doi: 10.1002/lt.21714.
  • Hoekstra J, Leebeek FW, Plessier A, Raffa S, Darwish Murad S, Heller J, et al. Paroxysmal nocturnal hemoglobinuria in Budd-Chiari syndrome: findings from a cohort study. J Hepatol. 2009;51(4):696–706. doi: 10.1016/j.jhep.2009.06.019.